How the major auto-titrating CPAP algorithms differ in flow-limitation sensitivity, ramp behaviour, response speed, and residual AHI.
Home Medix editorial teamLast updated 11 min read
Quick answer: APAP algorithms are not interchangeable: ResMed AutoSet generally responds earlier to flow limitation, while Philips, BMC, and other platforms use different event detection and pressure-response rules. There is no universally best algorithm; the useful choice is the one that controls a patient's events and flow limitation without unacceptable pressure swings, leaks, or discomfort, with data reviewed after the change.
Relevant Home Medix product information
Where a Home Medix model is listed below, its details are drawn from the published product specifications. Confirm the prescribed therapy and compare the current documentation for every device under consideration.
HM-CV-20 · CPAP / APAP — Published 4–20 cmH₂O pressure range, integrated humidification, ≤30 dB sound level and 1.45 kg weight.
Match the device to the prescription and compare the current technical documentation line by line. A shared category or range does not establish identical algorithms, accessories, certifications or clinical outcomes.
Frequently asked questions
Which APAP algorithm is best?
No algorithm is best for every patient. Compare residual event types, flow limitation, leak, pressure behaviour, symptoms, and comfort on actual download data rather than choosing from brand reputation alone.
Will two APAP machines set to the same range behave the same?
No. Detection thresholds and the speed and size of pressure changes differ by manufacturer, so two machines using the same minimum and maximum can produce different pressure profiles and residual AHI.
Should I switch APAP brands because my AHI is high?
First exclude mask leak, inadequate minimum pressure, central events, and poor adherence with a clinician. A different algorithm can help some patients, but a brand change is not a substitute for reviewing the cause.
An auto-titrating CPAP delivers pressure that varies breath-by-breath within a prescribed range, guided by the device's detection of flow limitation, snoring, and apnea events. The same patient on the same night, running two different APAPs within the same pressure range, will experience different average pressure, different 95th-percentile pressure, different residual AHI, and different flow-limitation control. The algorithms are not interchangeable, and the differences matter clinically — a patient whose therapy seems "adequate" on one brand and "marginal" on another is often seeing the algorithm difference, not a change in disease.
This article compares the major algorithms: ResMed AutoSet (on AirSense 10 / AirSense 11 / AirCurve), Philips Auto (DreamStation, DreamStation 2), BMC Auto (RESmart G3 / G4 and OEM variants), and the specific behaviours of each in flow-limitation response, ramp, AutoRamp, soft-start, and for-Her / gender-tuned variants. It closes with empirical evidence on residual-AHI differences and a note on Indian sleep-physician preferences.
HOME MEDIX PRODUCT INFORMATION
Explore sleep therapy equipment.
Compare published specifications, availability, service support, and current product documents before choosing a model with your care team.
ResMed AutoSet — AirSense 10, AirSense 11, AirCurve family
AutoSet is ResMed's algorithm family, running on essentially the entire current consumer range. The algorithm's design priorities:
Flow-limitation sensitivity is high. Inspiratory-waveform flattening is detected quickly, and pressure responds in small increments (0.5–1 cmH₂O per minute of sustained flattening).
Apnea discrimination via Forced Oscillation Technique (FOT): during a suspected apnea, the device emits a small pressure oscillation and measures the echo. Open airway (central apnea) echoes back; closed airway (obstructive) attenuates. Classification behaviour differs by platform and should be interpreted using current manufacturer documentation and clinical review.
Pressure-response curves favour not raising pressure for central apneas. When an apnea is classified central (ClearAirway), the algorithm does not increase pressure — because raising pressure doesn't help centrals and can worsen CompSAS.
Leak compensation is sophisticated. The algorithm recognises leak-driven flow fluctuations and discounts them, reducing the pressure-runaway failure mode that other algorithms sometimes exhibit.
AutoSet has two sub-variants:
AutoSet standard. Default algorithm for most adults.
AutoSet For Her. Gender-tuned: lower starting pressure, more gradual response curves, more weight to flow-limitation and snore events relative to frank apneas. Rationale is that female OSA phenotypes tend toward more UARS / flow-limitation-dominant presentations at lower mean pressures, and a less-aggressive algorithm is better tolerated. Evidence base is modest but consistent with the clinical observation.
In Indian clinical practice, AutoSet is commonly prescribed APAP algorithm at metro sleep-medicine centres, largely because of the perceived tight flow-limitation handling.
Philips Auto — DreamStation, DreamStation 2
Philips' Auto algorithm on DreamStation family uses a different architecture:
Apnea discrimination via a proprietary "cardiac pulse through the airway" signal — the arterial pulse transmitted through the airway is detected in the flow channel during an apnea, indicating airway patency. Clever but less definitive than ResMed's active FOT probe.
Flow-limitation detection is present but published evidence suggests lower sensitivity than ResMed, leading to higher residual flow-limitation index on equivalent patients.
Pressure-response curves are somewhat slower to react to sustained flow limitation and somewhat faster to react to apneas/hypopneas.
C-Flex pressure-relief is the default expiratory comfort feature (covered in a separate article). AutoRamp-equivalent feature is available.
Philips has traditionally positioned the DreamStation as comfort-focused rather than aggression-focused — the algorithm tolerates more residual flow limitation in exchange for smoother pressure profiles. Clinically, this means:
Comfort responses vary between patients and should be assessed during follow-up.
Residual AHI on DreamStation may run 0.5–1.5 events/hour higher than ResMed AirSense on equivalent patients.
Residual flow-limitation index is higher.
For uncomplicated OSA, suitability depends on prescribed settings, residual events, comfort, and follow-up data. For patients with flow-limitation-heavy phenotypes or incomplete response, the algorithm difference may matter.
The DreamStation 2 (newer generation, post-recall) retains the core algorithm philosophy but with refined hardware and improved cellular connectivity.
BMC Auto — RESmart G3, G4, and OEM variants
BMC is the widely available value-segment APAP brand in India, sold both under the BMC name and rebadged under various OEM names. The algorithm's characteristics:
Apnea discrimination — varies by firmware. Some generations use a pressure-pulse probe similar to ResMed FOT; others use flow-signal inference alone. Published documentation is thinner than for ResMed or Philips.
Flow-limitation sensitivity tends toward moderate — less aggressive than AutoSet, roughly comparable to Philips or slightly lower.
Pressure-response tends to be a little slower than both competitors in some firmware versions.
Leak compensation is present but less transparent in published behaviour.
The BMC algorithm is not "bad" — a well-configured BMC APAP at an appropriate pressure range produces acceptable residual AHI for straightforward moderate OSA. But the clinical documentation and cross-firmware consistency is weaker, meaning patient-to-patient outcomes are more variable than on AutoSet or DreamStation. In published small-cohort comparisons, BMC APAP residual AHI runs on average 0.5–2 events/hour higher than AutoSet on equivalent patients, with wider individual variance.
In Indian practice, BMC occupies the entry-level tier. Many first-time CPAP buyers start here because of price; a fraction later review an alternative with their clinician if residual therapy concerns emerge.
Ramp behaviour — soft-start, AutoRamp, fixed ramp
Ramp is the feature that lets a patient fall asleep at a lower pressure, ramping up to prescription pressure over a programmed window. Three variants:
Fixed ramp. Pressure starts at a low value (e.g., 4 cmH₂O) and climbs linearly to prescription pressure over a fixed time (e.g., 30 minutes). Simple and predictable. The drawback is that patients who fall asleep faster than ramp time are woken by the rising pressure; patients who fall asleep slower than ramp time are still at low pressure when they finally sleep, missing therapy for early events.
AutoRamp (ResMed term; similar concepts on Philips and BMC). The device detects sleep onset via flow-pattern changes (regularity, breath-to-breath variation) and begins the pressure ramp only after detecting sleep. Adapts to the patient's actual sleep-onset time. Reduces both waking and under-pressure issues of fixed ramp.
Soft start. A short (5–10 minute) initial-pressure-hold before climbing to prescription. Less flexible than AutoRamp; more flexible than no ramp.
ResMed AirSense 11 defaults to AutoRamp with sleep detection. Philips DreamStation 2 has a similar adaptive ramp feature. BMC offers configurable ramp with fixed or sleep-detect-like behaviour depending on firmware.
For patients with pressure intolerance at prescription levels, a 20–30 minute AutoRamp is the standard recommendation; for patients without tolerance issues, ramp can be shorter or disabled.
Empirical evidence — residual AHI and flow-limitation index
Direct head-to-head comparisons of APAP algorithms in published peer-reviewed literature are limited, largely because each manufacturer guards its algorithm internals. The available evidence, from various small-cohort and bench-model studies:
AutoSet vs DreamStation on matched patients. Residual AHI typically 0.5–1.5 events/hour lower on AutoSet. Residual flow-limitation index notably lower on AutoSet.
AutoSet vs BMC Auto. Residual AHI typically 0.5–2 events/hour lower on AutoSet, with wider individual variance on BMC across firmware versions.
DreamStation vs BMC. Roughly comparable at moderate OSA; DreamStation tends to pull ahead in complex patients and high-pressure scenarios.
These are averages; individual patient responses vary. A particular patient's sleep physiology may interact better with one algorithm than another in ways not predictable from the population average. The practical rule: the patient who is doing poorly on a less-tuned algorithm and still symptomatic should trial a tighter algorithm (usually AutoSet) before escalating to BiPAP or other therapy changes.
Note that residual AHI differences of 0.5–1.5 events/hour are clinically modest for well-treated patients (a patient at AHI 2.5 vs 1.0 is still well-treated). The differences become clinically meaningful in patients at the margin — AHI 5 vs 7 is the difference between "adequate" and "not adequate."
For-Her / gender-tuned variants
ResMed's AutoSet For Her is the one example: algorithm weights adjusted toward flow-limitation and RERA-equivalent events, lower pressure response to snoring alone, lower default starting pressure.
Rationale: female OSA phenotypes cluster toward:
Lower mean pressures at effective titration.
More prominent flow-limitation and RERA component.
More REM-dominant events.
Higher ratio of UARS-spectrum presentations.
Published validation of For Her showed modest reduction in residual AHI and better subjective comfort in female patients compared to standard AutoSet at the same prescription pressures. Philips has not offered a specific "For Her" algorithm variant; the DreamStation is a single algorithm for all patients. BMC similarly.
In Indian practice, AutoSet For Her is available but infrequently prescribed — partly because dealer awareness is low, partly because the gender-specific marketing doesn't translate culturally. Female OSA patients in metros whose clinicians are AASM-informed are more likely to receive it.
Indian sleep-physician preferences
From conversations with respiratory and sleep specialists across Indian metros and from observed prescribing patterns:
ResMed AirSense 10 / AirSense 11 is the default prescription choice at most major sleep-medicine centres in Mumbai, Delhi, Bengaluru, Chennai, and Hyderabad. The AutoSet algorithm's reputation for tight flow-limitation handling drives this.
Philips DreamStation 2 is a close second, particularly at centres with long-standing Philips relationships or Philips-heavy equipment ecosystems.
BMC G3 / G4 and OEM variants are prescribed at budget-conscious centres and at dealer-driven sales where patients select on price. Also common at tier-2 and tier-3 city practices where another brand service networks don't reach.
Home Medix HM-CV-20 belongs in the same CPAP/APAP shortlist on its published 4–20 cmH₂O range, integrated humidification, ≤30 dB sound level and 1.45 kg weight. Compare current algorithm documentation and report fields directly; no feature-for-feature algorithm equivalence is implied.
Manufacturer service networks in India are concentrated in metros. A patient in a smaller city buying ResMed or Philips should verify local service availability before committing — a warranty claim requires an authorised service point, and the nearest one may be 200+ km away.
Pressure-range settings — why a wide range isn't always better
APAP is often prescribed with a wide pressure range (say, 4–20 cmH₂O) on the theory that this gives the algorithm maximum latitude. In practice, the wider the range, the more the algorithm's behaviour dominates the therapy, and wide ranges can cause issues:
Wide ranges amplify algorithm differences. If you trial two APAPs on the same patient with range 4–20, the algorithmic differences between brands are fully exercised. A narrower range (say, 8–14, centred on the titrated pressure) constrains the algorithm and produces more consistent cross-brand behaviour.
4 cmH₂O is too low for most patients. The minimum pressure in a wide range is rarely useful — it's below the apneic threshold for essentially all OSA patients. Setting minimum at 6–7 cmH₂O saves the algorithm work and avoids the "patient woke up gasping because the machine was at 4" failure.
20 cmH₂O is rarely appropriate. If the algorithm needs to climb above 16–17 to control events, consider BiPAP instead.
A typical reasonable prescription: range (titrated 95th percentile minus 2) to (titrated 95th percentile plus 2), with the minimum floored at 6 cmH₂O. For a titrated 11 cmH₂O patient, range 9–14 is sensible.
The ResScan / DreamMapper / iCode dashboard — what each shows
Beyond the data itself, the clinician-facing and patient-facing dashboards differ:
ResMed myAir (patient) and AirView (clinician). Clean dashboards, strong trend graphing, straightforward download of raw SD card data. The myAir app gives patients a simple score and specific encouragement; AirView gives clinicians detailed patient lists and trend analytics. Widely used in Indian metros.
Philips DreamMapper (patient) and Care Orchestrator (clinician). Similar architecture, historically slightly less polished than ResMed's equivalents. Post-2021 recall-related complications affected some Indian DreamStation users' access to cellular uploads for a period.
BMC iCode. Web-based dashboard, variable in UI quality across versions. Patient-facing app less prominent than ResMed / Philips.
The dashboard matters for patient engagement. Patients who can see their own data tend to engage with therapy better and adhere longer. a particular algorithm paired with a clunky dashboard may still be the right clinical choice, but the lived patient experience is worse.
Clinical takeaway
APAP algorithms are not interchangeable. ResMed AutoSet leads in flow-limitation handling and central-apnea discrimination; Philips DreamStation favours comfort over aggression; BMC and budget variants are adequate for straightforward OSA but less robust for complex patients. Residual-AHI differences of 0.5–1.5 events/hour across algorithms are real, documented, and clinically meaningful for patients at the adequacy margin.
Clinical selection should be based on: first prescription at initiation should default to the tighter algorithm (AutoSet) in patients with predominantly obstructive OSA and accessible service networks. BMC and budget variants are defensible first-choices in price-sensitive contexts and for straightforward mild-moderate OSA, with escalation planned if residual therapy concerns emerge at 3–6 month follow-up.
For equipment information, compare the current specifications for the prescribed therapy and discuss suitability with the treating team. Product rankings are not a clinical recommendation.
Consult your sleep physician before switching between APAP brands or algorithms — the residual-AHI difference should be interpreted against your specific sleep physiology, not the population average.
